# CORRESP — Immix Biopharma, Inc.  (IMMX)  (CIK 0001873835)

> <strong>Immix Biopharma, Inc.  (IMMX)  (CIK 0001873835) → SEC staff</strong> · filed 2026-01-16 · ticker IMMX · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001493152-26-002680
- **Form:** CORRESP
- **Filer:** Immix Biopharma, Inc.  (IMMX)  (CIK 0001873835)
- **CIK:** 0001873835
- **Ticker:** IMMX
- **Filed:** 2026-01-16
- **SIC industry:** 2834
- **HQ:** Los Angeles, CA

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1873835/000149315226002680/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1873835&type=UPLOAD&dateb=&owner=include&count=40

## Other comment-letter activity for Immix Biopharma, Inc.  (IMMX)  (CIK 0001873835)

- UPLOAD — 2026-01-16 — /comment-letter/0000000000-26-000603
- CORRESP — 2025-11-26 — /comment-letter/0001493152-25-025192

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, Immix Biopharma, Inc.  (IMMX)  (CIK 0001873835) (CIK 0001873835), filed 2026-01-16, accession 0001493152-26-002680. Retrieved via MORVS 2026-11-15 from https://api.morvs.ai/comment-letter/0001493152-26-002680.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*